Clinical trials: Early Lung Cancer
Lung Cancer
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at…
- Trial name
- NCT05987189
- Testing
- Small RNA-based lung cancer assay
- Where
- 11 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Hummingbird Diagnostics
Non-small Cell Lung Cancer
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR of…
- Trial name
- CANOPY-N (NCT03968419)
- Testing
- Canakinumab, Pembrolizumab
- Where
- 29 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records. Increased lung cancer screening programs and increased utilization of other screening modalities such as…
- Trial name
- DIASTAG (NCT06842056)
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating…
- Trial name
- CheckMate 816 (NCT02998528)
- Testing
- Nivolumab, Cisplatin, Vinorelbine
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb
Peripheral Lung Tumor
Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer
Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is…
- Trial name
- NCT05918783
- Testing
- Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Impact Biotech Ltd
Lung Cancer, Pulmonary Neoplasm
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.
- Trial name
- BioMolCTC (NCT06546007)
- Testing
- CTC-DNA
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Rarecells Diagnostics SAS
Small Cell Lung Carcinoma
REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Primary lung cancer is one of the most common malignancies and causes of cancer-related death worldwide [Passiglia et al., 2019; Bade and Dela Cruz, 2020].
- Trial name
- ARAL (NCT06826677)
- Testing
- Durvalumab
- Where
- 11 sites in Italy
- Volunteers
- 71 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07195695
- Testing
- Zongertinib, Pembrolizumab, Atezolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim
Precancerous Conditions, Carcinoma
Early Diagnosis of Pulmonary Nodules
This study is intended to determine the positive predictive value (PPV) and negative predictive value (NPV) of the multiprotein classifier based on the observed study prevalence of Non-Small Cell Lung Cancer (NSCLC) in the study…
- Trial name
- NCT01752114
- Where
- 33 sites in United States, Canada
- Volunteers
- 684 people, healthy volunteers welcome
- Sponsor
- Integrated Diagnostics
Lung Cancers
Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
The goal of this observational study is to develop and evaluate a blood test for asymptomatic heavy smokers to screen for those at highest risk of developing lung cancer.
- Trial name
- NCT06816121
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Everest Detection, Inc.
Lung Cancer
To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer
This topic to take large multicenter study real world, the advanced liquid biopsy will ctDNA methylation detection technique is applied to pulmonary nodules differential diagnosis and early lung cancer screening, validation of…
- Trial name
- NCT05432128
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Singlera Genomics Inc.
Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal…
- Conditions
- Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
- Trial name
- CheckMate 9TN (NCT03770299)
- Testing
- Nivolumab, Vinorelbine, Gemcitabine
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early…
- Trial name
- STARS (NCT00840749)
- Testing
- CyberKnife Stereotactic Radiotherapy, Surgery
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 36 people
- Sponsor
- Accuray Incorporated
Non Small Cell Lung Cancer
A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer
The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.
- Trial name
- NCT01165021
- Testing
- Pemetrexed, Cisplatin, Folic Acid
- Where
- 7 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell-Lung Cancer
Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer
Based on available data, the concept of neo-adjuvant chemotherapy seems to be promising for patients with resectable non-small cell lung cancer. The exploration of new drugs and regimens are warranted.
- Trial name
- NCT00191763
- Testing
- Gemcitabine, cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Resectable, Early-stage
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA)…
- Conditions
- Resectable, Early-stage, NSCLC
- Trial name
- NCT03794544
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 84 people
- Sponsor
- MedImmune LLC
Lung Neoplasms
Breath Test for Early Detection of Lung Cancer
To demonstrate and validate a breath test for detection of early stage lung cancer that could potentially reduce number of deaths.
- Trial name
- NCT00639067
- Testing
- Breath Collection Apparatus
- Where
- 4 sites in United States
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Menssana Research, Inc.
Lung Cancer
Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
The purpose of this study is to determine whether availability of DNA Evaluation of Fragments for Early Interception (DELFI) Lung Cancer Screening Test, FirstLook™ to practicing physicians affects overall lung cancer screening…
- Trial name
- FIRSTLUNG (NCT06145750)
- Testing
- Ability to order FirstLook™, Continuing Medical Education for Lung Cancer
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Delfi Diagnostics Inc.
Lung Cancer, Non Small Cell Lung Cancer
Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy
The aim of this study is to sample and analyze volatile organic compounds (VOCs) from lung cancer patients and individuals without lung cancer ("healthy" controls).
- Trial name
- NCT04556435
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Breathe BioMedical Inc
Lung Cancer
Collection of Sputum and Labeling for Lung Cancer
The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection.
- Trial name
- NCT03457415
- Where
- 3 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- bioAffinity Technologies Inc.